NYSE:MED Medifast (MED) Stock Price, News & Analysis $12.22 -0.32 (-2.52%) Closing price 03:59 PM EasternExtended Trading$12.21 -0.01 (-0.11%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Medifast Stock (NYSE:MED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medifast alerts:Sign Up Key Stats Today's Range$12.16▼$12.6450-Day Range$11.44▼$13.3552-Week Range$9.22▼$13.63Volume70,361 shsAverage Volume138,600 shsMarket Capitalization$136.66 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingReduce Company Overview Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company’s approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company’s programs.AI Generated. May Contain Errors. Read More Medifast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreMED MarketRank™: 1.357910091495 of 5 starsMedifast scored higher than 27% of companies evaluated by MarketBeat, and ranked 140th out of 165 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingReduce Consensus RatingMedifast has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Medifast is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageMedifast has only been the subject of 2 research reports in the past 90 days.Read more about Medifast's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Medifast are expected to grow in the coming year, from ($0.57) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedifast has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.05% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 8.24.Change versus previous monthShort interest in Medifast has recently increased by 12.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment-0.47 News SentimentMedifast has a news sentiment score of -0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Medifast this week, compared to 3 articles on an average week.Search Interest4 people have searched for MED on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Medifast to their MarketBeat watchlist in the last 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,273,907.00 in company stock, which represents 0.9321% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have bought 562.93% more of their company's stock than they have sold. Specifically, they have bought $1,500,207.00 in company stock and sold $226,300.00 in company stock.Percentage Held by Insiders3.70% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MED Stock News HeadlinesMedifast (NYSE:MED) Cut to "Hold" at Zacks ResearchNovember 14 at 3:50 AM | americanbankingnews.comMedifast: 3 Key Takeaways for Long-Term InvestorsNovember 3, 2026 | fool.comThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 17 at 1:00 AM | Digest Publishing (Ad)Medifast (NYSE:MED) Director Parsa Kiai Buys 5,557 Shares of Company StockOctober 31, 2026 | insidertrades.comMED Q3 deep dive: new Trilogy brand and coach productivity drive evolving metabolic health strategyOctober 29, 2026 | uk.finance.yahoo.comMedifast Q3 Loss Widens, Sees Profit In Q4, Loss In FY26; Shares UpOctober 28, 2026 | rttnews.comMedifast Is Running The Same Playbook, And I Have The Same ConcernsOctober 28, 2026 | seekingalpha.comMedifast (MED) Q3 Results Deepen Losses As Coach Decline PersistsOctober 27, 2026 | finance.yahoo.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $10.66 at the beginning of the year. Since then, MED shares have increased by 14.7% and is now trading at $12.2240. How were Medifast's earnings last quarter? Medifast Inc (NYSE:MED) issued its quarterly earnings results on Monday, October, 26th. The specialty retailer reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.16. The specialty retailer had revenue of $72.05 million for the quarter, compared to the consensus estimate of $71.30 million. Medifast had a negative net margin of 13.64% and a negative trailing twelve-month return on equity of 6.90%. Read the conference call transcript. Who are Medifast's major shareholders? Top institutional shareholders of Medifast include Marshall Wace LLP (3.15%), Lido Advisors LLC (1.80%), Commons Capital LLC (1.65%) and Goldman Sachs Group Inc. (1.10%). Insiders that own company stock include Daniel R Chard, Scott Schlackman and Parsa Kiai. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Intel (INTC) and PayPal (PYPL). Company Calendar Last Earnings10/26/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MED's financial health is in the Green zone, according to TradeSmith. MED has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Personal Care Products Sub-IndustryPersonal Care Products Current SymbolNYSE:MED CIK910329 Webwww.medifastinc.com Phone(410) 581-8042Fax410-581-8070Employees380Year Founded1981Price Target and Rating Average Price Target for Medifast$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside-1.8%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($3.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.67 million Net Margins-13.64% Pretax Margin-9.73% Return on Equity-6.90% Return on Assets-5.34% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.32 Sales & Book Value Annual Sales$385.79 million Price / Sales0.35 Cash Flow$0.40 per share Price / Cash Flow30.21 Book Value$16.12 per share Price / Book0.76Miscellaneous Outstanding Shares11,180,000Free Float10,769,000Market Cap$136.66 million OptionableOptionable Beta0.65 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NYSE:MED) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.